Oncotarget

Research Papers:

FOXC1 promotes melanoma by activating MST1R/PI3K/AKT pathway and is associated with poor prognosis in melanoma

Jinhua Wang _, Li Li, Shiwei Liu, Ying Zhao, Lin Wang and Guanhua Du

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:84375-84387. https://doi.org/10.18632/oncotarget.11224

Metrics: PDF 1933 views  |   HTML 2554 views  |   ?  


Abstract

Jinhua Wang1,3, Li Li1, Shiwei Liu2, Ying Zhao1, Lin Wang1, Guanhua Du1

1The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of Drug Target Research and Drug Screen, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China

2Department of Endocrinology, Shanxi DAYI Hospital, Shanxi Medical University, Taiyuan, Shanxi 030002, China

3Department of Molecular Oncology, John Wayne Cancer Institute (JWCI) at Providence Saint John’s Health Center, Santa Monica 90404, CA, USA

Correspondence to:

Jinhua Wang, email: wjh@imm.ac.cn

Guanhua Du, email: dugh@imm.ac.cn

Keywords: FOXC1, cutaneous melanoma, MST1R/PI3K/AKT pathway, methylation

Received: April 20, 2016    Accepted: July 19, 2016    Published: August 11, 2016

ABSTRACT

FOXC1 is a member of Forkhead box family transcription factors. We showed that FOXC1 level was increased in melanoma cells and tissues and correlated with hypomethylation of the FOXC1 gene. Overexpression of FOXC1 promoted proliferation, migration, invasion, colony formation and growth in 3D Matrigel of melanoma cells. FOXC1 increased MST1R and activated the PI3K/AKT pathway. Also, FOXC1 expression was associated with disease progression and poor prognosis of melanoma. We suggest that FOXC1 is a potential prognostic biomarker for treating melanoma and predicting outcome of patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 11224